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Abstract
Background: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our
objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific
cancers in patients with diabetes.
Methods/Principal Findings: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and
ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and
meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic
patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of
11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort
studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-
metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49–0.88) for cancer mortality, 0.67 (0.53–0.85) for all-
cancer incidence, 0.68 (0.53–0.88) for colorectal cancer (n=6), 0.20 (0.07–0.59) for hepatocellular cancer (n=4), 0.67 (0.45–
0.99) for lung cancer (n=3).
Conclusion/Significance: The use of metformin in diabetic patients was associated with significantly lower risks of cancer
mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the
more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
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Introduction
Hyperinsulinemia and hyperglycemia are thought to promote
carcinogenesis in patients with diabetes mellitus. Several meta-
analyses have demonstrated that diabetes is associated with
increased risks of site-specific cancers of the breast (1.2) [1],
endometrium (2.1) [2], bladder (1.2) [3], liver (2.5) [4], colorectum
(1.3) [5], and pancreas (1.8–2.1) [6,7], and also a decreased risk of
prostate cancer (0.8–0.9) [8,9]. The evidence for non-Hodgkin’s
lymphoma remains inconclusive [10,11]. Our previous meta-
analyses showed that patients with diabetes have an inscreased risk
of total cancer (relative risk, 1.1–1.7) [12–14], whereas more
recent studies did not [15,16]. Metformin is an insulin sensitizer
that is the drug of first choice in the management of type 2
diabetes [17], given its safety profile and lower cost. Metformin
reportedly has a potential anti-cancer effect by activating
adenosine 59-mono-phosphate-activated protein kinase (AMPK)
in addition to alleviating hyperinsulinemia and hyperglycemia.
Although other mechanisms for this risk reduction have been
hypothesized, none have been elucidated entirely. Previous meta-
analyses have suggested that metformin is associated with a
reduced risk of cancer in diabetic subjects [18,19]. However, those
analyses were based solely on a few observational studies and
additional reports have been published recently.
In light of the worldwide diabetes epidemic and the higher
mortalities in cancer patients with diabetes [20,21], explorations of
effective cancer prevention are of clinical importance for the
targeted management of diabetes in daily practice. Moreover, they
are crucial in the areas of public health, since a modest increase in
the risk of cancer translates into a substantial social burden. These
circumstances prompted us to investigate, with greater precision,
the preventive effect of metformin on cancer mortality and
incidence by scrutinizing pertinent original reports including
randomized controlled trials (RCTs), and combining their data in
an attempt to obtain meaningful clues for the prevention of cancer
in patients with diabetes [13].
Methods
Search
Searches of MEDLINE, EMBASE, ISI Web of Science,
Cochrane Library, and ClinicalTrials.gov from their inception
until October 12, 2011, were performed. Studies evaluating the
risks of cancer mortality or incidence among diabetic patients
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20taking metformin, compared with those not taking metformin,
were identified using a combination of the following medical
subject heading terms: ‘diabetes’, ‘metformin’, ‘cancer’ or
‘neoplasms’, and ‘risk’ or ‘risk factors’. The reference lists of the
pertinent articles were also inspected.
Selection/Study Characteristics
We assessed all the identified RCTs, cohort studies, case-control
studies, and cross-sectional studies on the risk of cancer based on
original data analyses to determine their eligibility for inclusion in
a qualitative analysis. The inclusion criteria in the meta-analysis
are as follows: published full-text report in English-language,
RCTs with parallel-design of metformin as a treatment of type 2
diabetes at least one year’s follow-up period, observational studies
of any duration in patients with type 2 diabetes, reporting relative
risks, i.e. hazard ratios (HRs), RRs, or odds ratios, adjusted for
possible confounders with confidence intervals (CIs). The com-
parators were defined as any treatment not including metformin.
Validity assessment
To ascertain the validity of the eligible studies, the quality of
each report was appraised in reference to the CONSORT
statement [22] and the STROBE statement [23].
Data abstraction
We reviewed each full-text report to determine its eligibility and
extracted and tabulated all the relevant data independently. The
extracted data included the characteristics of the subjects
(including age, sex, and other treatment), study design, published
year, follow-up period, and the methods used for ascertaining the
diagnosis of cancer. Study authors were contacted as needed to
obtain detailed data. Any disagreement was resolved by a
consensus among the investigators.
Quantitative data synthesis
If more than one study was published for the same cohort, the
report containing the most comprehensive information on the
population was included to avoid overlapping populations. The
reports were summarized both qualitatively and quantitatively.
Three articles that did not specify the case numbers were not
included in the calculation of the mortality and incidence. If the
metformin comparator included more than one treatment, the oral
monotherapy groups were included in the analysis because these
groups were deemed to be at an equivalent stage of diabetes. If an
article provided the relative risks for all cancer and site-specific
cancers, the all cancer data were included in the primary
qualitative and quantitative analyses and the site-specific data
were used in the secondary analyses performed according to
cancer site. The risks for site-specific cancers were appraised if
three or more qualified reports were identified for a given cancer
site. Response to metformin exposure was evaluated by using
linear-regression analysis.
In the meta-analysis, each adjusted relative risk was combined
and the pooled RRs with the 95% CI was calculated using the
random-effects model with inverse-variance weighting. Heteroge-
neity among the studies was evaluated using I
2 statistics. The
possibility of a publication bias, which can result from the non-
publication of small studies with negative findings, was assessed
visually using a funnel plot for asymmetry. RevMan (version 5.1)
was used for these calculations. A sensitivity analysis was
performed by separating the RCTs and the observational cohort
/ case-control studies and the equality of RRs between RCTs and
observational studies were assessed by using z-statistic tests. All the
procedures were in accordance with the guidelines for the Quality
of Reporting of Meta-analyses [24], the meta-analysis of
observational studies in epidemiology [25] and the PRISMA
statement [26].
Results
Search Results
A total of 412 articles were identified during our search; of
these, 32 were assessed with respect to their eligibility for inclusion
in our review, which was aimed at determining the influence of
metformin on cancer mortality and incidence in patients with
diabetes (Fig. 1). Four articles [27–30] were excluded from the
systematic review because of population overlapping and four
other reports were excluded because they investigated the overall
survival rate [31,32], cancer incidence exclusively in patients with
hepatitis C [33], and biochemical recurrence [34]. Out of these 32
articles, a total of 24 (11 observational cohort studies [35–45], 3
randomized controlled trials [46–49], and 10 case-control studies
[29,50–58]) were included in the systematic review and meta-
analysis. The UK Prospective Diabetes Study (UKPDS) 34 [49]
involved two independent investigational trials (metformin vs.
conventional therapy and sulfonylurea vs. sulfonylurea plus
metformin), and these trials were included in the meta-analysis
as two separate data.
Table S1 shows the characteristics of each included study
according to the study design. The 24 selected articles included in
the systematic review were moderately heterogeneous in terms of
population demographics, study design, and the assessment of
confounding factors. The diabetes sample size in these studies
ranged from 361 to 998,947 patients. Of the 21,195 diabetic
patients in 6 studies, 991 (4.5%) cases of cancer death were
reported. A total of 11,117 (5.3%) cases of incident cancer at any
site were reported among 210,892 patients in 10 studies. Major
confounding factors such as cigarette smoking, alcohol intake, and
hyperglycemia were not reported in several studies.
The risk of bias and the adjustment factors among the studies
are summarized in Table S2. Diabetes was diagnosed using blood
tests (n=8), prescription databases (n=6), medical records (n=4),
self-reports (n=3), and health insurance database (n=4). All the
diagnoses of cancer were confirmed using valid records or
registries. All the studies, except for the RCTs, adjusted the
estimates for potential confounding factors. The analysis of dose-
response was performed in 3 studies [38–40]. Some studies
excluded the data for metformin exposure less than 1 year [50,52]
or 2 years [58] to minimize bias. The effect on the total cancer risk
over the follow-up period was inspected in 3 studies [40,55,58].
Direct comparison of the effect between metformin and other
specific medications were reported in 2 RCTs [46–48].
Qualitative Summary
The majority of the studies included were methodologically fair
in quality. Among 10 case-control studies, six were nested ones
[50–52,55,56,58]. All the four cohort studies [35,38,40,41] on
cancer mortality revealed a significant decrease (range, 23%–
75%), and the two RCTs showed no significant effect of
metformin [49]. There was no study that directly compared the
risk associated with metformin vs other medications or analyzed
the correlation between the follow-up length and the effect of
metformin on cancer mortality. The overall correlation of the
follow-up period with the mortality was nonsignificant (r=20.04,
p=0.9). One study revealed that the HR (95% CI) for cancer
mortality with every increase of 1 g metformin was 0.58 (0.36–
0.93) [38].
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studies [55,56]) reported a significant decrease (range, 26%–88%),
the two RCTs showed no significant effect of association [46–48]
and none demonstrated a statistically significant increase in the
risk of all-cancer incidence among metformin users. The cancer
risk for metformin users was not significantly different from that
for rosiglitazone or sulfonylurea users in RCTs [46–48]. One
cohort study showed a trend for metformin users to have a higher
risk of cancer in the first 2 years of follow-up. The beneficial effect
of metformin on the risk of total cancer incidence was exposure-
dependent in 2 case-control studies [55,56]. The overall
correlation of the follow-up period with the incidence was
nonsignificant (r=20.32, p=0.4). One study reported that its
effect on cancer incidence was dose-dependent (p for trend
,0.05) [39] suggesting that the minimal effective dose can be
500 mg /day, while the other showed no significant differences
among doses [40].
Among the studies evaluating the risks of site-specific incident
cancers in patients with diabetes who were taking metformin,
more than two studies (including subgroup analyses) recognized
significantly reduced risks for cancers of the pancreas [36,39,54],
colorectum [36,39,40], and liver [29,39,53], and none showed a
significantly increased risk of a site-specific cancer. All these risk
decrements were moderate (RR range, 0.06–0.60). Of note, no
significant increases or decreases in the risk of cancers of the
breast, prostate or stomach were reported, except for a significant
decrease in the risk of prostate cancer in one report [42] and breast
cancer in another [52]. The number of studies examining other
cancer sites was two or fewer, and these studies were not reviewed
in the present analysis.
Quantitative Summary (Meta-analysis)
Based on the quality appraisal in our systematic review, a total
of 24 articles that provided sufficient information were included in
the meta-analysis (Fig. 1). Fig. 2 illustrates the significantly
decreased risks of all-cancer mortality and incidence in metformin-
users, compared with non-metformin users. In a sensitivity
analysis, the pooled estimate (95% CI) for all-cancer mortality
among the observational cohort studies was 0.62 (0.46–0.82),
I
2=56%, p=0.08 and the estimate among the RCTs was 1.22
(0.36–4.11), I
2=60%, p=0.12. The difference in the RRs
between the observational studies and the RCTs was not
statistically significant (p=0.35). The pooled RR (95% CI) for
all-cancer incidence among the observational cohort studies was
0.66 (0.49–0.88), I
2=96%, p,0.00001, the pooled RR among the
case-control studies was 0.38 (0.23–0.61), I
2=3%, p=0.31 and
the estimate among the RCTs was 1.03 (0.82–1.31), I
2=30%,
p=0.23. The difference in the RRs between the observational
studies and the RCTs was statistically significant (p=0.019). As
summarized in Fig. 3 and Fig. 4, the incident cancer risks were
also significantly decreased for cancers of the colorectum, liver and
lung. The RRs of prostate cancer, breast cancer, pancreatic cancer
and gastric cancer were not statistically significant. Significant
heterogeneity was observed in the majority of these analyses. No
apparent publication bias was apparent, as assessed using a funnel
plot (Fig. S1).
Discussion
Our systematic review and meta-analyses of worldwide reports
demonstrated that metformin is associated with a substantially
lower risk of all-cancer mortality and incidence, compared with
other treatments for diabetes. They also showed that metformin
significantly reduced the risks of cancers of the colorectum, liver
and lung. These findings support the hypothesis that metformin
potentially has an anti-cancer effect. In light of the fact that cancer
is the second and diabetes the twelfth leading cause of death
worldwide [59] and that the number of people with diabetes is
rapidly increasing, our findings have substantial clinical and public
implications on a global scale and point to the need for the further
investigation of the anti-cancer mechanism of metformin and for
long-term RCTs to confirm this clinical benefit.
Figure 1. Flow diagram of study selection.
doi:10.1371/journal.pone.0033411.g001
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based on large population-based data originating from multiple
nations and was performed with a high level of precision.
Compared with recently published studies [18,19], our updated
study is novel in that data from RCTs were incorporated and
cancer risks for substantially more sites were analyzed. Although
the significantly decreased pooled RRs for all-cancer mortality /
incidence and cancer at most sites were robust, the results of the
component studies were statistically heterogeneous. Of note, all
the individual and pooled results of the RCTs were neutral. It
seems that each follow-up period in these RCTs is similar to many
others in the observational studies and they have power enough to
detect the differences in cancer risk. In the analysis of cancer
mortality, there was no significant difference in RR between the
RCTs and the observational studies. For cancer incidence, on the
other hand, the overall RR was significantly reduced but the
difference was statistically significant. This discordance may imply
that the apparent anti-cancer effect of metformin in observational
studies was affected by confounding biases and thus more RCTs
are awaited to clarify the effect of metformin on cancer incidence.
The large I
2 values indicated that the range of the plausible risk
estimates was wide but no evidence in our analysis suggested that
metformin may increase the risk of cancer. These findings may
reflect the different mechanisms of cancer prevention at different
sites and / or different epidemiological characteristics among the
diverse populations included in our study.
Evidence has been accumulating to suggest that diabetic
patients have a higher risk of cancer than non-diabetic people
[12,13]. While the mechanisms are yet to be investigated, insulin
resistance with secondary hyperinsulinemia is the most frequently
proposed hypothesis, as insulin may have a possible mitogenic
effect via its binding to the insulin-like growth factor-1 receptor
Figure 2. Adjusted risk ratios for all-cancer mortality and incidence among subjects with diabetes taking metformin. Boxes,
estimated risk ratios (RRs); bars, 95% confidence intervals (CIs). Diamonds, random-effects model RRs; width of diamonds; pooled CIs. The size of each
box is proportional to the weight of each study in the meta-analysis. *, randomized controlled trials; **, case-control studies; IV, inverse-variance.
doi:10.1371/journal.pone.0033411.g002
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genesis directly [71,72] or indirectly by increasing oxidative stress
[73–79]. However, these speculations are derived from retrospec-
tive observational studies and may not necessarily demonstrate
causality because of possible biases and confounders, such as co-
existing obesity and age [15,80,81]. In fact, more recent studies
demonstrated no or minimal increments in cancer risk [15,16] and
the data from insulin-treated patients are inconclusive [82]. Of
interest, diabetes reportedly protects against the development of
prostate cancer [8,9], since it is testosterone-dependent and
testosterone deficiency is common among men with diabetes
secondary to low levels of sex hormone-binding globulin (SHBG)
Figure 3. Adjusted risk ratios for site-specific cancer incidence among subjects with diabetes taking metformin. Boxes, estimated risk
ratios (RRs); bars, 95% confidence intervals (CIs). Diamonds, random-effects model RRs; width of diamonds; pooled CIs. The size of each box is
proportional to the weight of each study in the meta-analysis. *, randomized controlled trials; **, case-control studies; IV, inverse-variance.
doi:10.1371/journal.pone.0033411.g003
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estimated risk ratios (RRs); bars, 95% confidence intervals (CIs). Diamonds, random-effects model RRs; width of diamonds; pooled CIs. The size of each
box is proportional to the weight of each study in the meta-analysis. *, randomized controlled trials; **, case-control studies; IV, inverse-variance.
doi:10.1371/journal.pone.0033411.g004
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levels may facilitate the conversion of testosterone to estradiol,
which in turn may result in an increased risk of hormone-
dependent breast cancer.
Several mechanisms for the anti-cancer effect of metformin
have been postulated, and several prospective clinical trials to
evaluate its safety and efficacy are ongoing [82,86]. Indirect
pathways include the prevention of weight gain and the
amelioration of hyperinsulinemia, both of which may promote
carcinogenesis. In addition, metformin activates AMPK through
LKB-1, a tumor suppressor protein kinase. AMPK inhibits
protein synthesis and gluconeogenesis during cellular stress and
inhibits mammalian target of rapamycin (mTOR), a downstream
effector of growth factor signaling, which is frequently activated
in malignant cells. In human breast cancer cells, it reduces HER-
2 protein expression by inhibiting mTOR. Metformin also
induces cell cycle arrest and apoptosis and reduces growth factor
signaling. Supporting the idea of these direct effects, metformin
reportedly potentiated the effect of neoadjuvant chemotherapy in
early-stage breast cancer [87], decreased the risk of colorectal
cancer in a small randomized trial involving non-diabetic subjects
[88], and was associated with a decreased cancer risk while
another insulin-sensitizer, thiazolidinedione, were not [18,54,
89,90].
Our research revealed that metformin use is associated with
reduced mortality and incidence of cancer at any site, supporting
the general applicability of the proposed anti-cancer mechanisms.
The anti-cancer effect of metformin may also be applicable to
diabetic Asians, who are generally lean and insulinopenic [12],
given the fact that they have a higher cancer risk than non-
diabetic Asians [12–14] and the data for Asians [39] were in line
with the results of our meta-analyses. On the other hand, the
magnitude of the risk reduction varies among site-specific
cancers. This variance in efficacy may result from differences in
carcinogenesis at certain sites. For instance, elevated levels of
insulin and glucose may exert an important influence in the
development or growth of epithelial malignant tumors of the
colon [91–93], pancreas [94,95], and breast [96], and metformin
may prevent incident colon cancer in non-diabetic subjects [88].
An animal study suggested that metformin prevented smoking-
related lung cancer in mice, probably by inducing some hormone
from the liver [97]. With regard to sex hormone-dependent
cancers, the effect of metformin on the development of prostate
cancer and breast cancer in our analysis was neutral. Metformin
improves insulin sensitivity, thereby possibly raising the testos-
terone level. This may have promoted prostate cancer develop-
ment and may have diluted the beneficial effect of metformin. In
fact, one cohort study reported no benefit of metformin in terms
of the biochemical recurrence rate after radical prostatectomy in
diabetic patients [34]. The nonsignificant pooled RR for breast
cancer may have resulted from the diversity in confounder
adjustments and follow-up periods: some analyses were not fully
adjusted for risk factors, including the menopause status, and one
study suggested that only long-term exposure to metformin
reduced the risk of breast cancer [51]. The fact that one
preliminary study suggested a promising effect of metformin on
pathologic complete responses to neoadjuvant chemotherapy in
diabetic patients with breast cancer [87] may point to the
possibility that metformin simply augmented the efficacy of
chemotherapy for breast cancer [18,86]. Further detailed studies
to analyze the interaction between carcinogenesis and the action
of metformin, and to evaluate its effect for nondiabetic people are
eagerly awaited.
Limitations
Our analysis should be interpreted in the context of the following
limitations. First, the relation may not necessarily be causal,
particularly in the observational studies [80], because of possible
confounding factors and biases that may not have been fully adjusted
for in this study: some risk factors such as cigarette smoking, alcohol
intake, and hyperglycemiawere not specified in severalstudies,which
may have rendered the results less valid. Few studies demonstrated
the dose-response to support biological plausibility. Confounding by
treatment indication [98], which may have been minimizes by using
propensity-score matching analysis, might overestimate the effect of
metformin: the presence of such pre-existing conditions as older age
and liver disease precludes metformin usages and thus, metformin
users may be generally younger and at lower risk of cancer than in
those in comparator groups. Only a few observational studies
analyzed the effects over time and thus protopathic bias (i.e. early
cancer leading to unstable diabetes and hyperglycemia, with patients
switching diabetes treatment) [15] may remain moderate. In fact, the
individual and pooled estimates from the RCTs were all neutral; the
estimates comparing with other medication were neutral, as well. For
all these limitations, however, observational studies provide the good
available evidence regarding potential treatment effects / harms and
the overall pooled estimates were robust. Moreover, evidence has
been accumulating to support causality, both clinically and
biochemically, as discussed earlier. Secondly, it is also important to
realize that the populations of the studies were heterogeneous, most
likely because of the diversity of the study designs and ethnicities, and
that the sensitivity of each site-specific cancer to metformin may vary.
Lack of the standardized treatment protocol in the descriptive studies
might explain the observed associations: the possibility that other
diabetes treatments may increase the risk of cancer may have resulted
in an overestimation of the effect of metformin. Lack of the
standardized diagnostic procedures for cancer may have caused
detection bias in some cases. Even with these limitations, our analysis
supports oncogenic safety of metformin and it should provide
physicians with an additional incentive to pay integrated clinical
attention and elucidate the complex interactions between diabetes
treatment and cancer.
Conclusions
Our meta-analysis favors the oncogenic benefit of metformin for
diabetic patients. However, observational studies were moderately
heterogeneous and biased, and RCTs did not show a significant
effect. Our findings underscore the need for long-term randomized
prospective studies to confirm this potential benefit.
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